MDAI vs AEYE vs GMED vs ALKT vs SYK

For growth investors, Spectral AI, Inc.

(MDAI) is the stronger pick with 63. 8% revenue growth year-over-year, versus 11. 2% for Stryker Corporation (SYK). Globus Medical, Inc. (GMED) offers the better valuation at 21. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Globus Medical, Inc. (GMED) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Globus Medical, Inc.

(GMED) is the cheapest at 21. 7x versus Stryker Corporation at 35. 0x. On forward P/E, Globus Medical, Inc. is actually cheaper at 19. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Globus Medical, Inc. wins at 0. 61x versus Stryker Corporation's 1. 32x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -76. 9% for Spectral AI, Inc. (MDAI). Over 10 years, the gap is even starker: GMED returned +264. 4% versus MDAI's -76. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 318% more volatile than SYK relative to the S&P 500. On balance sheet safety, Globus Medical, Inc. (GMED) carries a lower debt/equity ratio of 3% versus 98% for Alkami Technology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Spectral AI, Inc.

(MDAI) is pulling ahead at 63. 8% versus 11. 2% for Stryker Corporation (SYK). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to -12. 2% for Alkami Technology, Inc.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Globus Medical, Inc.

(GMED) is the more profitable company, earning 18. 3% net margin versus -51. 8% for Spectral AI, Inc. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -22. 3% for MDAI. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Globus Medical, Inc. (GMED) is the more undervalued stock at a PEG of 0. 61x versus Stryker Corporation's 1. 32x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Globus Medical, Inc. (GMED) trades at 19. 0x forward P/E versus 21. 7x for Alkami Technology, Inc. — 2. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SYK: 37. 2% to $403. 69.

In this comparison, SYK (1.

1% yield) pays a dividend. MDAI, AEYE, GMED, ALKT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). AudioEye, Inc. (AEYE) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, AEYE: +102. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MDAI (Healthcare) and AEYE (Technology) and GMED (Healthcare) and ALKT (Technology) and SYK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MDAI is a small-cap high-growth stock; AEYE is a small-cap quality compounder stock; GMED is a mid-cap high-growth stock; ALKT is a small-cap high-growth stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while MDAI, AEYE, GMED, ALKT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.